E-resources
Peer reviewed
-
Gawronski, Kristen M., PharmD; Goff, Debra A., PharmD, FCCP; Jack Brown, PharmD, MS; Khadem, Tina M., PharmD; Bauer, Karri A., PharmD, BCPS
Clinical therapeutics 35, Issue: 6Journal Article
Abstract Background Current guidelines for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia recommend targeting a vancomycin AUC24 /MIC ≥400. Data on the association between AUC24 /MIC and microbiological clearance in patients with concomitant MRSA bacteremia and MRSA osteomyelitis are limited. Objective The objective of this study is to evaluate the association between the vancomycin AUC24 /MIC and time to microbiological clearance in patients with concomitant MRSA bacteremia and MRSA osteomyelitis. Methods Adult inpatients with concomitant MRSA bacteremia and MRSA osteomyelitis treated with vancomycin from January 1, 2007, through December 31, 2011, were evaluated. Classification and regression tree analysis was used to identify the AUC24 /MIC associated with time to microbiological clearance. Results Fifty-nine patients had complete data available for review and were included in the analysis. Classification and regression tree analysis identified an AUC/MIC of 293 as the breakpoint that provides the greatest difference in time to microbiological clearance. On univariate analysis, mean (SD) time to clearance was 2 days shorter when the AUC/MIC was >293 (4 2 days vs 6 3 days, P = 0.01). Mean (SD) infection-related length of stay was 13 (6) versus 18 (14) days in patients with an AUC24 /MIC ratio >293 or ≤293, respectively ( P = 0.25). In patients with an AUC24 /MIC ≤293, 39% versus 17% ( P = 0.09) had recurrent bacteremia and were readmitted compared with patients with an AUC/MIC >293. Only 9% were able to achieve an AUC24 /MIC >293 when the vancomycin MIC was >1 μg/mL. Conclusions We observed a >2.5-fold increase in time to microbiological clearance in patients with concomitant MRSA bacteremia and MRSA osteomyelitis unable to achieve a vancomycin AUC24 /MIC >293. A 5-day increase in hospital and infection-related length of stay was observed when this target was not achieved. Recurrence of bacteremia and hospital readmissions were higher in the cohort who did not achieve an AUC24 /MIC >293. Only 9% of patients were able to achieve an AUC24 /MIC >293 if the isolate MIC was >1 μg/mL. Trough concentration did not correlate with AUC24 /MIC. In patients with concomitant MRSA bacteremia and MRSA osteomyelitis treated with vancomycin, stewardship programs should optimize pharmacodynamic parameters, specifically AUC24 /MIC, or alternative therapies should be considered.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.